Posted 23 July, 2026
Founded in Ames, Narrate AR, Inc., doing business as Ama AI, is developing a personalized artificial intelligence platform to help children with autism and other cognitive differences receive more consistent support across home, school and therapy settings. The platform is designed to reinforce therapy goals, improve communication and provide caregivers and clinicians with insights to better track progress. A $100,000 Demonstration Fund loan will support commercialization efforts by refining the platform for Applied Behavior Analysis providers, improving onboarding and reporting tools, integrating with provider systems, enhancing security and compliance, expanding market outreach and protecting intellectual property as the company prepares for broader adoption.
SoilSerdem, LLC in Ames is developing advanced geospatial software that helps agronomists analyze yield, soil and spatial field data more quickly and accurately, improving decision-making for farmers and agricultural retailers. Designed to integrate with existing precision agriculture platforms, the company’s tools streamline workflows while enhancing soil sampling and mapping, and yield analysis. A $100,000 Demonstration Fund loan will support commercialization by expanding market-entry efforts, refining products based on customer feedback, building strategic partnerships, validating new applications in the carbon market and accelerating adoption across the agriculture industry.
University of Iowa spin-off Juggernaut Life Sciences in Coralville is developing a minimally invasive laser-based medical device designed to improve the treatment of early-stage cancers by allowing physicians to target tumors more precisely while reducing damage to surrounding healthy tissue. The platform is intended to make cancer treatment safer and more efficient and has potential applications in melanoma, liver and thyroid cancers. A $50,000 Proof of Commercial Relevance loan will support intellectual property development and evaluation, proof-of-concept work, product refinement and equipment as the company advances the technology toward clinical use.
Award recommendations for these funds are made by the Technology Commercialization Committee to the IEDA Board for approval.